


Roquinimex

| | | | |
|---------------------------|---|-------|---------|
| Cat. No.: | HY-13743 | | |
| CAS No.: | 84088-42-6 | | |
| Molecular Formula: | C ₁₈ H ₁₆ N ₂ O ₃ | | |
| Molecular Weight: | 308.33 | | |
| Target: | TNF Receptor | | |
| Pathway: | Apoptosis | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 2 years |
| | | -20°C | 1 year |



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 83.3 mg/mL (270.17 mM)
 * "≥" means soluble, but saturation unknown.

| Concentration | Mass | | |
|---------------|-----------|------------|------------|
| | 1 mg | 5 mg | 10 mg |
| 1 mM | 3.2433 mL | 16.2164 mL | 32.4328 mL |
| 5 mM | 0.6487 mL | 3.2433 mL | 6.4866 mL |
| 10 mM | 0.3243 mL | 1.6216 mL | 3.2433 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Roquinimex (Linomide; PNU212616; ABR212616) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity; inhibits angiogenesis and reduces the secretion of TNF alpha. IC50 value: Target: TNF alpha. Prophylactic administration of DSS-treated mice with roquinimex significantly reduced clinical signs of colitis, MDS and the CH-reduction. Moreover, in roquinimex treated animals, the MPO activity was significantly reduced by more than 50% compared to DSS control mice. Notably, therapeutic administration of roquinimex in DSS-treated mice also significantly inhibited the MDS, CH-reduction and MPO activity [2]. Linomide, a synthetic immunomodulator, at concentrations effective in vivo reduces the number of MBP-reactive TNF-alpha and increases MBP-reactive IL-10 and TGF-beta mRNA expressing MNC from MS patients' blood when analysed in vitro. Compared to dexamethasone, Linomide up-regulated levels of blood MNC expressing mRNA of TGF-beta after culture in presence of MBP [3].

REFERENCES

[1]. Roquinimex, From Wikipedia

[2]. Liu Q, et al. Roquinimex inhibits dextran sodium sulfate-induced murine colitis. *Inflamm Res*. 2003 Feb;52(2):64-8.

[3]. Tian WZ, et al. Linomide (roquinimex) affects the balance between pro- and anti-inflammatory cytokines in vitro in multiple sclerosis. *Acta Neurol Scand*. 1998 Aug;98(2):94-101.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA